---
title: "Zepbound Plateau: Tirzepatide Titration at 5, 10 and 15 mg"
description: "A guide to Zepbound (tirzepatide) dose titration, plateau management, and evidence-based strategies to restart weight loss at 5 mg, 10 mg, and 15 mg doses."
url: https://healthrx.com/titration-zepbound/plateau-strategy
publisher: HealthRX.com
---


HealthRX.com

At 15 mg a plateau is expected; below it, a dose step may help

2.5 mg Dose step, taken after 4 or more weeks on current dose Source: Eli Lilly and Company, FDA-approved label

[Print or save as PDF](https://healthrx.com/printables/titration-zepbound/plateau-strategy?print=1)

Key numbers

- 15 mg Maximum weekly Zepbound dose for all indications Source: [Eli Lilly and Company, FDA-approved label](https://pi.lilly.com/us/zepbound-uspi.pdf), checked Oct 18, 2026
- 6.7 weeks Extra time to weight plateau at 15 mg vs 5 mg in the analysis Source: [Clinical Obesity, 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC12096058/), checked Oct 18, 2026
- 2.5 mg Dose increase step, taken after at least 4 weeks on the current dose Source: [Eli Lilly and Company, FDA-approved label](https://pi.lilly.com/us/zepbound-uspi.pdf), checked Oct 18, 2026

[See the public record for Tirzepatide](https://healthrx.com/data/tirzepatide)

HealthRX.com quick answer. A plateau on Zepbound 15 mg is common and is not proof that the drug stopped working. In the SURMOUNT trials weight loss levelled off for most people by about week 72, and higher doses plateaued later, not earlier. There is no approved dose above 15 mg, so the options at the top dose are to check the basics (timing, missed doses, other medicines), keep taking it, because stopping led to regain in SURMOUNT-4, and ask your clinician about diet, activity and other treatment. Below 15 mg, the FDA label lets the dose rise in 2.5 mg steps after at least 4 weeks on the current dose.

At a glance

- Drug / Zepbound ([tirzepatide](https://healthrx.com/zepbound)), once-weekly subcutaneous injection
- Starting dose / 2.5 mg weekly for 4 weeks (initiation only, not a maintenance dose)
- Titration interval / Increase in 2.5 mg steps after at least 4 weeks on the current dose
- Maintenance doses for weight reduction / 5 mg, 10 mg or 15 mg weekly
- Maximum approved dose / 15 mg weekly
- Mean weight change at 72 weeks, 5 / 10 / 15 mg (SURMOUNT-1) / 15.0% / 19.5% / 20.9% (placebo 3.1%)
- Plateau definition used in trial analyses / Weight change under 5% over a 12-week interval and every later 12-week interval
- Time to plateau at 10 and 15 mg vs 5 mg / 4.4 and 6.7 weeks later on average
- GI side effects / Mostly during dose escalation, and they decreased over time in the trials

## What Is a Zepbound Efficacy Plateau?

A Zepbound plateau is the point where weight stops falling and holds roughly steady despite consistent weekly injections. Researchers who studied this in the SURMOUNT trials used a precise rule: weight change of under 5% over a 12-week interval, and over every later 12-week interval. They describe the plateau as the transition from negative energy balance to neutral energy balance and, ideally, the start of long-term weight maintenance [(Horn et al., Clin Obes 2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12096058/).

That same paper says a plateau is often mistakenly read as the end of a treatment's benefit or as loss of treatment effect. In SURMOUNT-1, by week 72, 87.6% to 90.2% of participants who lost at least 5% of their weight had reached a plateau, depending on their starting BMI category. A plateau is the usual end point of a weight-loss phase, not an unusual event.

### Why Dose Matters More Than Time on Drug

In SURMOUNT-1, people assigned to higher doses lost more weight on average over the same 72 weeks. Mean weight change was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, against 3.1% on placebo [(Jastreboff et al., NEJM 2022)](https://pubmed.ncbi.nlm.nih.gov/35658024/). Counting only the time people stayed on treatment, the same trial reported averages of 16.0%, 21.4% and 22.5%, against 2.4% on placebo. Going from 5 mg to 15 mg added nearly 6 percentage points of body weight lost on average. A stall at a lower dose is therefore a different problem from a stall at 15 mg, where the dose ladder has no further rung.

### Distinguishing a True Plateau from Expected Deceleration

The rate of loss declines over time during obesity treatment before it reaches a plateau. Three questions help separate a real plateau from a dip or a dosing problem:

- **How long has it lasted?** The trial definition uses a 12-week window, so a few flat weeks is not a plateau by that standard.
- **Is there a dose left to try?** If the current dose is below 15 mg and is tolerated, the label allows a step up after at least 4 weeks on that dose.
- **Were the injections on schedule?** [Missed injections](https://healthrx.com/zepbound/missed-dose-protocol) and late doses are the first thing to rule out, and the label sets a window for missed doses, covered in the injection section below.

Printable titration log

Zepbound stall check: weight trend, dose history and injection timing

Use this before you decide your weight has stalled: twelve weeks of weigh-ins next to your dose and injection dates, a check of the things that look like a plateau but are not, and the questions to take to your prescriber.

[Open the fill-in sheet](https://healthrx.com/printables/titration-zepbound/plateau-strategy) Fill it in, print it or save it as a PDF. No sign-up.

## Plateau at 15 mg: What the SURMOUNT Trials Show and Your Options

Reaching 15 mg and then stalling is common enough that it was studied directly. This section covers when weight loss levels off in the trials and what the label and the trial data support doing at the top dose.

### When Weight Loss Levels Off in SURMOUNT

The weight-loss curve flattens for most participants within the 72 to 88 weeks of the trials. In the SURMOUNT-1 plateau analysis, median time to plateau was 24.3 weeks for people with overweight, 26.0 weeks for class I obesity, and 36.1 weeks for both class II and class III obesity. By week 72, 90.2%, 88.9%, 87.6% and 87.8% of participants across those four BMI categories had reached a plateau. Results in SURMOUNT-4 were similar [(Horn et al., Clin Obes 2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12096058/).

The higher the dose, the later the plateau. The paper reports:

Mean time to weight plateau was 4.4 and 6.7 weeks longer with tirzepatide 10 and 15 mg, respectively, compared with tirzepatide 5 mg

The same analysis found a plateau also came later in younger people and in women. In plain terms, plateauing while on 15 mg is the expected course for the group that lost the most.

### What Is the Weight Loss at 15 mg?

| Result at week 72, SURMOUNT-1 | Placebo | 5 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- |
| Mean change in body weight | 3.1% | 15.0% | 19.5% | 20.9% |
| Lost at least 5% | 34.5% | 85.1% | 88.9% | 90.9% |
| Lost at least 10% | 18.8% | 68.5% | 78.1% | 83.5% |
| Lost at least 15% | 8.8% | 48.0% | 66.6% | 70.6% |
| Lost at least 20% | 3.1% | 30.0% | 50.1% | 56.7% |

Source: the Zepbound prescribing information, Table 2 (Study 1).. These are group averages in people without [type 2 diabetes](https://healthrx.com/conditions-type-2-diabetes/diagnosis-algorithm). In the Zepbound label's diabetes trial (Study 2), mean weight change at 72 weeks was 12.8% at 10 mg and 14.7% at 15 mg, so a smaller total loss at 15 mg is expected in people with type 2 diabetes.

### What the Label Says About the Top Dose

The label text on escalation and the ceiling reads:

The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose

The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.

The label also says to consider treatment response and tolerability when selecting the maintenance dosage, and to consider a lower maintenance dosage if a dose is not tolerated [(Zepbound prescribing information)](https://pi.lilly.com/us/zepbound-uspi.pdf). Nothing in the label approves a dose above 15 mg, and the label does not say a plateau should be treated by changing the dose once 15 mg has been reached.

### Options When You Plateau at 15 mg

| Option | What the sources support |
| --- | --- |
| Check dosing basics | The label gives a 4-day (96 hour) window for a missed dose, and says the weekly dosing day can be moved if at least 3 days (72 hours) separate two doses. Weekly injections in the wrong rhythm are worth ruling out first. |
| Keep taking it | In SURMOUNT-4, people who stayed on tirzepatide after the lead-in lost a further 5.5% on average from week 36 to week 88. People switched to placebo regained 14.0%. 89.5% of those who continued kept at least 80% of their lead-in weight loss. |
| Stay with diet and activity | Zepbound is indicated with a reduced-calorie diet and increased physical activity. The label trials gave about a 500 kcal per day deficit and at least 150 minutes per week of activity counseling. |
| Review other medicines | The label warns that insulin or an insulin secretagogue such as a sulfonylurea raises hypoglycemia risk with Zepbound. Ask your clinician to review every medicine you take. |
| Do not add another tirzepatide or GLP-1 product | The label says taking Zepbound with another tirzepatide-containing product or any GLP-1 receptor agonist is not recommended. |
| Ask about other treatment | If you have been on 15 mg and are not satisfied, a conversation with your clinician about next steps is appropriate. The trials above do not test switching treatments, so no switching claim is made here. |

Because a plateau often reflects the body settling at a new energy balance, maintaining the weight already lost is itself a treatment outcome. The Horn analysis notes that some people have a short plateau followed by regain soon after reaching their lowest weight, and that continued [tirzepatide](https://healthrx.com/products/tirzepatide) in SURMOUNT-4 maintained the initial weight reduction as well as producing additional reduction compared with withdrawal.

### When Slow Early Loss Is Not the Same Thing

If your problem is slow loss early on, not a stall at 15 mg, the SURMOUNT-1 data are encouraging. A post hoc analysis defined late responders as those with under 5% weight loss at week 12. They made up 18% of the people analysed, and 90% of them reached at least 5% weight loss by week 72 [(Ard et al., Diabetes Obes Metab 2025)](https://pubmed.ncbi.nlm.nih.gov/40677091/). The authors conclude that extending treatment well beyond 12 weeks may allow more people to reach a clinically meaningful loss.

## The FDA-Approved Zepbound Titration Schedule

The Zepbound prescribing information specifies a stepwise escalation beginning at 2.5 mg. The recommended starting dosage is 2.5 mg injected once weekly for 4 weeks, and the 2.5 mg dose is for starting treatment and is not approved as a maintenance dose. The label then continues [(Zepbound prescribing information)](https://pi.lilly.com/us/zepbound-uspi.pdf):

After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose

The recommended maintenance dosage for weight reduction and long-term maintenance is 5 mg, 10 mg or 15 mg once weekly.

### Step-by-Step Dose Escalation Table

| Week Range | Dose | Primary Goal |
| --- | --- | --- |
| Weeks 1-4 | 2.5 mg | Initiation dose |
| Weeks 5-8 | 5.0 mg | First maintenance option |
| Weeks 9-12 | 7.5 mg | Step up if tolerated |
| Weeks 13-16 | 10.0 mg | Maintenance option |
| Weeks 17-20 | 12.5 mg | Step up if tolerated |
| Week 21 onward | 15.0 mg | Maximum approved dose |

This table shows the fastest path the label's wording allows, with a 2.5 mg step every 4 weeks. The label asks prescribers to consider response and tolerability, so many people stop at 5 mg or 10 mg or take longer on each step. The label states these steps; it does not list skipping a 2.5 mg step, so any other pattern is a decision for your prescriber.

### Minimum Time to Maximum Dose

If each step is tolerated, the earliest a person can be on 15 mg is week 21, which is after 20 weeks of escalation. In SURMOUNT-1 the dose escalation period lasted up to 20 weeks, followed by the maintenance period.

## SURMOUNT-1: What the Key Trial Shows About Dose and Outcomes

SURMOUNT-1 was a phase 3 randomized controlled trial of 2,539 adults with obesity (BMI of 30 or more), or with overweight (BMI 27 to under 30) and at least one weight-related complication, excluding diabetes. Participants were assigned in a 1:1:1:1 ratio to tirzepatide 5 mg, 10 mg or 15 mg, or placebo, once weekly for 72 weeks, including a dose-escalation period of up to 20 weeks [(NEJM 2022)](https://pubmed.ncbi.nlm.nih.gov/35658024/).

### Primary Efficacy Results by Dose

At 72 weeks, mean percentage weight change from baseline was:

- **5 mg group:** 15.0% loss (vs. 3.1% placebo)
- **10 mg group:** 19.5% loss (vs. 3.1% placebo)
- **15 mg group:** 20.9% loss (vs. 3.1% placebo)

All three doses differed from placebo with P below 0.001. For a person starting at 100 kg, the gap between the 5 mg and 15 mg averages is about 6 kg of body weight. That is a group average, not a promise for one person, and body weight includes more than fat.

### Responder Rates

The share of participants losing 20% or more of body weight was 30.0% at 5 mg, 50.1% at 10 mg and 56.7% at 15 mg, against 3.1% on placebo, per the label. Stopping the trial drug was uncommon: adverse events led to discontinuation in 4.3%, 7.1% and 6.2% of the 5 mg, 10 mg and 15 mg groups, and 2.6% on placebo.

### Plateau Timing in the Trial Arms

The Horn analysis of SURMOUNT-1 and SURMOUNT-4 is the best source on timing. It found that most participants who adhered to treatment reached a plateau by week 72, with higher doses, younger age and female sex linked to a later one. A plateau at 15 mg after a long period of loss fits that pattern. A stall in the first months at 5 mg is a different situation, because the label provides further steps up.

Figure 1

Median weeks to a weight plateau in SURMOUNT-1, by starting BMI

In this post hoc SURMOUNT-1 analysis, a plateau meant less than 5% weight change over a 12-week interval and every 12-week interval after it, which is not the same as a few flat weeks on the scale. It covers 1438 participants, all doses pooled, who received at least 75% of their study doses and lost at least 5% by week 72; by then 87.6% to 90.2% of each BMI group had plateaued. Among those who plateaued, in a model adjusting for age, sex, race and body size, the plateau came on average 4.4 weeks later on 10 mg and 6.7 weeks later on 15 mg than on 5 mg. Doses were fixed by randomization, so the analysis does not show what a dose increase after a plateau would do. Source: [Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials](https://pmc.ncbi.nlm.nih.gov/articles/PMC12096058/), abstract, methods, statistical models [3] .

Show the numbers behind this chart

Median weeks to a weight plateau in SURMOUNT-1, by starting BMI

| Starting BMI | Median weeks to plateau |
| --- | --- |
| Overweight (BMI 27 to under 30) | 24.3 |
| Class I obesity (BMI 30 to under 35) | 26.0 |
| Class II obesity (BMI 35 to under 40) | 36.1 |
| Class III obesity (BMI 40 or more) | 36.1 |

A Zepbound loss so far, set beside SURMOUNT trial participants

Pick the SURMOUNT checkpoint and dose closest to the current one, type the percent of starting weight lost, and see how many trial participants on tirzepatide sat in that same band of loss.

Your result: Percent of starting weight lost on Zepbound Reference group

Type a result to see which band it falls in. Reference group: Week 72 on 5 mg, SURMOUNT-1 (mean loss 16.0%).

Percent of starting weight lost on Zepbound: Week 72 on 5 mg, SURMOUNT-1 (mean loss 16.0%). Source: [ClinicalTrials.gov results record for SURMOUNT-1 (NCT04184622), National Library of Medicine](https://clinicaltrials.gov/study/NCT04184622?tab=results), Nov 13, 2026

| Band | Range | What the source says |
| --- | --- | --- |
| Under 5% lost, or weight gained | below 5% | 89.4% of people on tirzepatide 5 mg had lost at least 5% of their starting weight at week 72 of SURMOUNT-1, so about 10.6% had lost less than that or gained. |
| 5% to under 10% lost | 5 to under 10% | 89.4% of people on tirzepatide 5 mg had lost at least 5% at week 72 of SURMOUNT-1 and 73.4% at least 10%, which leaves about 16.1% in this band. |
| 10% to under 15% lost | 10 to under 15% | 73.4% of people on tirzepatide 5 mg had lost at least 10% at week 72 of SURMOUNT-1 and 50.2% at least 15%, which leaves about 23.1% in this band. |
| 15% to under 20% lost | 15 to under 20% | 50.2% of people on tirzepatide 5 mg had lost at least 15% at week 72 of SURMOUNT-1 and 31.6% at least 20%, which leaves about 18.6% in this band. |
| 20% or more lost | 20% and above | 31.6% of people on tirzepatide 5 mg had lost at least 20% of their starting weight at week 72 of SURMOUNT-1. |

Show the other 3 reference groups as tables

Percent of starting weight lost on Zepbound: Week 72 on 10 mg, SURMOUNT-1 (mean loss 21.4%). Source: [ClinicalTrials.gov results record for SURMOUNT-1 (NCT04184622), National Library of Medicine](https://clinicaltrials.gov/study/NCT04184622?tab=results), Nov 13, 2026

| Band | Range | What the source says |
| --- | --- | --- |
| Under 5% lost, or weight gained | below 5% | 96.2% of people on tirzepatide 10 mg had lost at least 5% of their starting weight at week 72 of SURMOUNT-1, so about 3.8% had lost less than that or gained. |
| 5% to under 10% lost | 5 to under 10% | 96.2% of people on tirzepatide 10 mg had lost at least 5% at week 72 of SURMOUNT-1 and 85.9% at least 10%, which leaves about 10.3% in this band. |
| 10% to under 15% lost | 10 to under 15% | 85.9% of people on tirzepatide 10 mg had lost at least 10% at week 72 of SURMOUNT-1 and 73.6% at least 15%, which leaves about 12.2% in this band. |
| 15% to under 20% lost | 15 to under 20% | 73.6% of people on tirzepatide 10 mg had lost at least 15% at week 72 of SURMOUNT-1 and 55.5% at least 20%, which leaves about 18.1% in this band. |
| 20% or more lost | 20% and above | 55.5% of people on tirzepatide 10 mg had lost at least 20% of their starting weight at week 72 of SURMOUNT-1. |

Percent of starting weight lost on Zepbound: Week 72 on 15 mg, SURMOUNT-1 (mean loss 22.5%). Source: [ClinicalTrials.gov results record for SURMOUNT-1 (NCT04184622), National Library of Medicine](https://clinicaltrials.gov/study/NCT04184622?tab=results), Nov 13, 2026

| Band | Range | What the source says |
| --- | --- | --- |
| Under 5% lost, or weight gained | below 5% | 96.3% of people on tirzepatide 15 mg had lost at least 5% of their starting weight at week 72 of SURMOUNT-1, so about 3.7% had lost less than that or gained. |
| 5% to under 10% lost | 5 to under 10% | 96.3% of people on tirzepatide 15 mg had lost at least 5% at week 72 of SURMOUNT-1 and 90.1% at least 10%, which leaves about 6.2% in this band. |
| 10% to under 15% lost | 10 to under 15% | 90.1% of people on tirzepatide 15 mg had lost at least 10% at week 72 of SURMOUNT-1 and 78.2% at least 15%, which leaves about 11.8% in this band. |
| 15% to under 20% lost | 15 to under 20% | 78.2% of people on tirzepatide 15 mg had lost at least 15% at week 72 of SURMOUNT-1 and 62.9% at least 20%, which leaves about 15.4% in this band. |
| 20% or more lost | 20% and above | 62.9% of people on tirzepatide 15 mg had lost at least 20% of their starting weight at week 72 of SURMOUNT-1. |

Percent of starting weight lost on Zepbound: Week 88, continued arm of SURMOUNT-4 (mean loss 26.0%). Source: [ClinicalTrials.gov results record for SURMOUNT-4 (NCT04660643), National Library of Medicine](https://clinicaltrials.gov/study/NCT04660643?tab=results), Nov 13, 2026

| Band | Range | What the source says |
| --- | --- | --- |
| Under 5% lost, or weight gained | below 5% | 98.5% of people assigned to continue their highest tolerated tirzepatide dose had lost at least 5% of their starting weight at week 88 of SURMOUNT-4, so about 1.5% had lost less than that or gained. |
| 5% to under 10% lost | 5 to under 10% | 98.5% of people assigned to continue their highest tolerated tirzepatide dose had lost at least 5% at week 88 of SURMOUNT-4 and 94.0% at least 10%, which leaves about 4.5% in this band. |
| 10% to under 15% lost | 10 to under 15% | 94.0% of people assigned to continue their highest tolerated tirzepatide dose had lost at least 10% at week 88 of SURMOUNT-4 and 87.1% at least 15%, which leaves about 6.9% in this band. |
| 15% to under 20% lost | 15 to under 20% | 87.1% of people assigned to continue their highest tolerated tirzepatide dose had lost at least 15% at week 88 of SURMOUNT-4 and 72.6% at least 20%, which leaves about 14.5% in this band. |
| 20% or more lost | 20% and above | 72.6% of people assigned to continue their highest tolerated tirzepatide dose had lost at least 20% of their starting weight at week 88 of SURMOUNT-4. |

SURMOUNT-1 enrolled adults with obesity or overweight and no diabetes. SURMOUNT-4 kept only people who got through a 36-week lead-in, so its week 88 arm is selected. Posted means are model estimates that count time on the drug only. These are group results, not a forecast for one person.

For education only. This tool shows what the cited sources say; it does not diagnose anything or set a dose. Talk with your clinician before you change how you take a medicine.

## Practical Plateau-Breaking Strategies by Clinical Scenario

Different plateau patterns call for different responses. The approach below follows what the label and trials support, and where they are silent, it says so.

### Scenario 1: Plateau at 5 mg Before Week 16

The dose ladder is not finished. The label allows a step up in 2.5 mg increments after at least 4 weeks on the current dose, and 5 mg, 10 mg and 15 mg are all listed maintenance doses. In SURMOUNT-1 the mean loss rose with each dose. Before escalating, confirm:

1. Injections are happening about once every 7 days, within the label's missed-dose window.
2. The injection site is one the label lists (abdomen, thigh, or the back of the upper arm, which another person should inject) and sites are rotated.
3. Your clinician has reviewed your other medicines.

If those check out and the current dose is tolerated, discuss a dose increase with your prescriber.

### Scenario 2: Plateau at 10 mg After 3 to 4 Months of Good Loss

Check whether the stall has lasted long enough to count. The trial analyses define a plateau over a 12-week window, and loss tends to slow gradually before it stops. If it persists and the current dose is tolerated, the label allows 12.5 mg or 15 mg. The label does not set a maximum time on any dose, and the choice of timing is the prescriber's.

### Scenario 3: Plateau at 15 mg (Maximum Dose)

This is the case covered in detail in the section above on plateauing at 15 mg. In short, there is no higher approved dose. The sourced options are to confirm dosing and timing, to keep taking the medicine because continued treatment maintained and added to weight reduction in SURMOUNT-4, to stay with the reduced-calorie diet and activity the label pairs it with, to review other medicines such as insulin or a sulfonylurea, and to talk to your clinician about whether anything else is right for you. [A medication reconciliation review](https://healthrx.com/zepbound/drug-drug-interactions) is the simplest way to catch insulin or a sulfonylurea on your list. [Resistance training preserves lean mass](https://healthrx.com/lifestyle-zepbound/exercise) while you lose weight, so strength sessions are a sensible part of the activity you keep up at the top dose. The trials do not provide evidence on adding another weight-loss drug, so that question belongs with a clinician who knows your history.

What people on Reddit report

Accounts from Zepbound and tirzepatide compounding forums about whether to raise the dose during a stall and how they made the call.

cloratheshadow · Zepbound

If you haven't lost weight in over a month and you're pretty hungry, go up to 7.5! I'm at 10 after 5 months and only in the higher doses have I had consistent results.

Reports that a stall plus hunger was reason to go up, and that results felt consistent only at higher doses.

[Read the source discussion](https://www.reddit.com/r/Zepbound/comments/1vj3exe/after_initial_whoosh_my_weight_loss_has_stalled/)

marshdd · Zepbound

The last 20 are HARD. Consider upping your dose. You've been plateauing for a LONG time, a small change isn't going to do it.

Argues that a long plateau needs a real dose change rather than small adjustments.

[Read the source discussion](https://www.reddit.com/r/Zepbound/comments/1sijmy9/10month_stall_on_zepbound_down_63_lbs_what/)

CrosslyCute · tirzepatidecompound

That sweet craving creepin back is annoying, but if you're still losing 1-2 lbs a week I'd probably ride it out a bit longer.

Suggests waiting before raising the dose because weight was still dropping steadily.

[Read the source discussion](https://www.reddit.com/r/tirzepatidecompound/comments/1uhdjq8/has_anyone_titrated_up_due_to_decrease_in_food/)

Questions worth asking

Choose the questions you want to keep Is my weight loss stall long enough to justify a dose increase? Should I check my injection day and technique before changing my dose? Could any of my other medications be reducing how well Zepbound works? What side effects should I expect in the first weeks after a dose increase? If I am already at my maximum dose, what other options should we discuss?

## Managing GI Side Effects During Titration

The most common reason people delay or avoid escalation is gastrointestinal side effects. In the label's pooled weight-reduction trials, nausea occurred in 8% on placebo and 25%, 29% and 28% of people on 5 mg, 10 mg and 15 mg. Diarrhea was 8% on placebo and 19%, 21% and 23% on the three doses, and vomiting was 2% on placebo and 8%, 11% and 13%. Overall, gastrointestinal adverse reactions occurred in 56% at each dose against 30% on placebo.

### When nausea and diarrhea cluster

[GI side effects cluster](https://healthrx.com/side-effects-zepbound-nausea/timeline) in the escalation period: the label says most nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. Each new dose step is a new adjustment period, so doing well at one dose does not guarantee the next will be symptom-free. Treatment was stopped for gastrointestinal reasons in 1.9% at 5 mg, 3.3% at 10 mg and 4.3% at 15 mg, against 0.5% on placebo.

### Practical Mitigation Steps

- Inject on a consistent day each week at a time that allows observation of symptoms (e.g., a Friday evening injection lets the patient manage Saturday nausea without missing work).
- Eat smaller portions at each meal for the first 2 weeks after any dose increase.
- Avoid high-fat, fried, or heavily spiced foods during the initial adaptation period.
- Stay hydrated. The label notes that acute kidney injury has been reported mainly after nausea, vomiting or diarrhea led to dehydration, and that kidney function should be monitored in people with these reactions, especially during initiation and escalation.
- Report persistent or severe stomach pain, especially pain that moves to the back, since the label directs stopping the drug if pancreatitis is suspected.
- If symptoms do not settle at a new dose, tell your prescriber. The label says to consider a lower maintenance dosage if a dosage is not tolerated.

### When to Hold or Reduce Dose

The label tells prescribers to consider treatment response and tolerability when selecting the maintenance dose. A lower dose is a labelled option when a higher one is not tolerated, and it can be the right long-term dose for some people.

## Real-World Titration Patterns vs. Trial Protocols

Trial protocols fix the dose of each arm, and the label says to individualize the maintenance dose. In the label's trial of randomized withdrawal (Study 4), people escalated over up to 20 weeks to a maximum tolerated dose of 10 mg or 15 mg, and at week 36, 93% of those randomized were on 15 mg and 7% on 10 mg. The trial also illustrates that an individual's best dose is the highest one they tolerate, which is why the label allows 5 mg, 10 mg or 15 mg as maintenance doses.

The trial participants also received a lifestyle program. The label describes instruction on a reduced-calorie diet with about a 500 kcal per day deficit and activity counseling of at least 150 minutes per week. Results in everyday practice depend on dose, adherence and these supports together.

### Compounded Tirzepatide: A Note on Dosing Equivalence

During the FDA drug shortage period, compounded tirzepatide became widely prescribed. Compounded formulations are not FDA-approved and do not carry the same purity, potency, or sterility guarantees as the branded Eli Lilly product. Dosing protocols from compounding pharmacies varied widely. Patients transitioning from compounded to branded Zepbound should work with their prescriber to re-establish the correct dose tier rather than assuming their compounded dose was equivalent. [The FDA has published its concerns about unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss), which covers compounded tirzepatide and is worth reviewing.

## Monitoring Parameters During Titration

Safe titration involves more than the scale.

### What to Monitor at Each Dose Step

- **Body weight:** Weigh at the same time of day under similar conditions, and look at the trend over several weeks, since the trial plateau definition covers 12 weeks.
- **GI symptoms:** Note nausea, vomiting and diarrhea after each dose step, and fluid intake if symptoms are heavy.
- **Kidney function:** The label advises monitoring in people who have adverse reactions that could cause volume depletion, especially during initiation and escalation.
- **Blood sugar and other medicines:** Zepbound lowers blood glucose. In the label's diabetes trial, hypoglycemia rose to 10.3% with a sulfonylurea against 2.1% without one, and the label also lists increased risk with insulin.
- **Thyroid warning:** Zepbound carries a boxed warning for thyroid C-cell tumors based on rodent data and is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

### Frequency of Follow-Up Visits

The label does not set a visit schedule. Ask your prescriber how often to check in during escalation, and bring a record of your weight, doses and symptoms.

## Injection Technique and Its Effect on Drug Exposure

A plateau is a reason to review basics before assuming the drug is failing. The label asks prescribers to train patients on the exact presentation they are using, whether vial, prefilled pen or KwikPen, and to retrain if the presentation changes.

### Correct Injection Technique

- Inject once weekly at any time of day, with or without meals.
- Use the abdomen, thigh, or the back of the upper arm (another person should inject there).
- Rotate injection sites with each dose.
- If a dose is missed, take it as soon as possible within 4 days (96 hours). After more than 4 days, skip it and take the next dose on the regular day.
- The weekly day can be changed if at least 3 days (72 hours) separate the two doses.

If injections seem less effective than before, review these points with your prescriber or pharmacist before any dose change.

## When to Consider Discontinuation or Transition

The strongest evidence on stopping is from SURMOUNT-4. [Abrupt discontinuation of Zepbound](https://healthrx.com/zepbound/discontinuation-protocol) there meant a switch to placebo: after a 36-week lead-in with 20.9% average weight loss, those people regained 14.0% by week 88, while people who continued tirzepatide lost a further 5.5%. The authors concluded that withdrawing tirzepatide led to substantial regain, whereas continued treatment maintained and augmented the initial reduction [(Aronne et al., JAMA 2024)](https://pubmed.ncbi.nlm.nih.gov/38078870/).

That is the reason a plateau alone is not a reason to stop. If you cannot tolerate your dose, the label's answer is a lower maintenance dose. If you are unhappy with your results or have side effects that do not settle, ask your prescriber about next steps and about a plan for maintaining weight before you change or stop treatment.

Figure 2

Slow start on tirzepatide: weight lost by week 72 after less than 5% at week 12

Late responders had lost less than 5% by week 12 (278 of 1545 participants, 18%); early responders had lost 5% or more. Among late responders, 70% had reached 5% by week 24, at the end of dose escalation, and 90% by week 72; the mean time to reach 5% was 24.8 weeks. Only participants who took at least 75% of their assigned doses are included, and doses were assigned at randomization rather than raised for slow progress. Post hoc analysis of SURMOUNT-1. Source: [SURMOUNT-1 early-response analysis (Ard et al., 2025)](https://pubmed.ncbi.nlm.nih.gov/40677091/), abstract, results 3.3 [5] .

Show the numbers behind this chart

Slow start on tirzepatide: weight lost by week 72 after less than 5% at week 12

| Group | Mean weight change at week 72 (%) |
| --- | --- |
| Late responders on 5 mg | −8.3 |
| Late responders on 10 mg | −11.4 |
| Late responders on 15 mg | −13.6 |
| All late responders | −11.0 |
| All early responders | −22.5 |

Try the tool

Tirzepatide dose calculator and dosage chart

Convert a tirzepatide dose between mg, mL and U-100 syringe units, with the 2.5 to 15 mg label chart.

[Open the dose calculator](https://healthrx.com/tools/tirzepatide-dose-calculator)

Frequently asked questions

How quickly can you increase Zepbound?

The FDA label allows a dose increase in 2.5 mg steps after at least 4 weeks on the current dose. Starting at 2.5 mg for 4 weeks, the fastest schedule reaches 5 mg at week 5, 7.5 mg at week 9, 10 mg at week 13, 12.5 mg at week 17 and 15 mg at week 21 if every step is tolerated. The label also asks prescribers to consider response and tolerability, so many people move more slowly.

What is the maximum dose of Zepbound?

The maximum dosage of Zepbound for all indications is 15 mg injected subcutaneously once weekly, according to the FDA label. No higher dose is approved.

Why did I plateau on Zepbound 15 mg?

Weight loss levels off for most people on tirzepatide. In the SURMOUNT-1 and SURMOUNT-4 analysis, a plateau was defined as under 5% weight change over each 12-week interval, and most participants had reached one by week 72. Higher doses reached it later, by an average of 6.7 weeks at 15 mg compared with 5 mg. The authors describe it as the shift from losing weight to holding it.

What can I do if I plateau on Zepbound 15 mg?

There is no approved dose above 15 mg. Confirm your injections are on schedule, review your other medicines with your clinician, keep up the reduced-calorie diet and physical activity the medicine is paired with, and ask about further options. In SURMOUNT-4, people who continued tirzepatide lost a further 5.5% on average while those switched to placebo regained 14.0%.

Is it normal to stop losing weight on Zepbound?

Yes. The rate of weight loss declines over time and eventually reaches a plateau. In SURMOUNT-1, 87.6% to 90.2% of adherent participants who lost at least 5% had reached one by week 72, depending on BMI category.

What should I do if Zepbound seems to have stopped working?

First check the basics: weekly timing, how you handle a missed dose, injection sites and your other medicines. If you are below 15 mg and tolerating the dose, ask whether the next 2.5 mg step makes sense. If you are at 15 mg, talk with your clinician about the options, and do not stop on your own because stopping led to regain in SURMOUNT-4.

Can you go back to a lower Zepbound dose if side effects are bad?

Yes. The label says to consider a lower maintenance dosage if a maintenance dosage is not tolerated. The recommended maintenance doses for weight reduction are 5 mg, 10 mg and 15 mg.

Does Zepbound work better at 10 mg or 15 mg?

In SURMOUNT-1, mean weight loss at 72 weeks was 19.5% at 10 mg and 20.9% at 15 mg. The share of people losing at least 20% of body weight was 50.1% at 10 mg and 56.7% at 15 mg. Both are group averages, and your own response can differ.

How do I know if my Zepbound dose is high enough?

The label does not set a target for each dose and asks prescribers to consider treatment response and tolerability. In SURMOUNT-1 the average results rose from 5 mg to 10 mg to 15 mg. If you are below 15 mg, plateauing and tolerating your dose, ask your prescriber whether the next step is right for you.

Can diet changes help break a Zepbound plateau?

Zepbound is indicated alongside a reduced-calorie diet and increased physical activity, and the label trials included about a 500 kcal per day deficit and activity counseling. The trials did not test a specific diet change at 15 mg, so ask your clinician or a dietitian what makes sense for you.

Does exercise help break a Zepbound plateau?

The label pairs Zepbound with increased physical activity and its trials included at least 150 minutes per week of activity counseling. The sources reviewed here do not measure how much exercise restarts weight loss at a plateau.

How long should I stay on Zepbound?

The label indicates Zepbound to reduce excess body weight and maintain weight reduction long term. In SURMOUNT-4, people who stopped tirzepatide for placebo regained 14.0% of their weight by week 88, while those who continued lost a further 5.5%.

Can Zepbound weight loss stop completely?

At a stable dose, yes, and that is the normal course. The researchers who analysed SURMOUNT-1 and SURMOUNT-4 describe the plateau as the transition from negative to neutral energy balance, and note that it is often mistakenly seen as the end of the treatment's benefit. Holding the lower weight becomes the goal.

References

Show all 8 references Hide references

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. [Tirzepatide once weekly for the treatment of obesity (PubMed 35658024)](https://pubmed.ncbi.nlm.nih.gov/35658024/)
2. Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. Revised 08/2026. [pi.lilly.com: zepbound uspi](https://pi.lilly.com/us/zepbound-uspi.pdf)
3. Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025;15(3):e12734. [Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials (PubMed Central PMC12096058)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12096058/)
4. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. [Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial (PubMed 38078870)](https://pubmed.ncbi.nlm.nih.gov/38078870/)
5. Ard J, Lee CJ, Gudzune K, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes Obes Metab. 2025;27(9):5064-5071. [Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1 (PubMed 40677091)](https://pubmed.ncbi.nlm.nih.gov/40677091/)
6. Reddit participants. [After initial "whoosh" my weight loss has stalled. Thought 5 mg was answer but more wt loss w/ 2.5. Should I titrate up ? (r/Zepbound)](https://www.reddit.com/r/Zepbound/comments/1vj3exe/after_initial_whoosh_my_weight_loss_has_stalled/). Accessed 2026-11-10.
7. Reddit participants. [10-month stall on Zepbound (down 63 lbs) What actually helped you break a long plateau? (r/Zepbound)](https://www.reddit.com/r/Zepbound/comments/1sijmy9/10month_stall_on_zepbound_down_63_lbs_what/). Accessed 2026-11-10.
8. Reddit participants. [Has anyone titrated up due to decrease in food noise suppression without stall in weight loss? 2.5 mg (r/tirzepatidecompound)](https://www.reddit.com/r/tirzepatidecompound/comments/1uhdjq8/has_anyone_titrated_up_due_to_decrease_in_food/). Accessed 2026-11-10.

Next in this cluster

Related reading

- [tirzepatide Mounjaro for weight loss](https://healthrx.com/off-label-mounjaro/weight-loss--evidence-summary)
- [tirzepatide Zepbound switching](https://healthrx.com/reviews-zepbound/switching-reports)
- [tirzepatide STEP-1 vs SURMOUNT-1](https://healthrx.com/glp-1/compare-step1-surmount1)
- [tirzepatide Surmount 1 trial](https://healthrx.com/glp-1/surmount-1-trial)
- [tirzepatide Compounded tirzepatide](https://healthrx.com/access-zepbound/compounded-equivalent)
- [tirzepatide Zepbound HSA/FSA Eligibility and Submission](https://healthrx.com/access-zepbound/hsa-fsa-eligibility)
- [tirzepatide Zepbound Medicare Advantage coverage](https://healthrx.com/access-zepbound/medicare-advantage)
- [tirzepatide Zepbound Medicare Part D Coverage: What to Expect in 2026](https://healthrx.com/access-zepbound/medicare-part-d)
- [tirzepatide Restart Zepbound after break](https://healthrx.com/titration-zepbound/re-titration-after-stop)
- [tirzepatide Zepbound appetite changes](https://healthrx.com/zepbound-v2/appetite-cravings-changes)
- [tirzepatide Zepbound restarting after acute illness](https://healthrx.com/zepbound-v2/post-illness-restart)
- [tirzepatide Zepbound Pre-Surgery hold window](https://healthrx.com/zepbound-v2/pre-surgery-window)
- [tirzepatide Tirzepatide cardiovascular impact Long-Term](https://healthrx.com/zepbound/cardiovascular-impact)
- [tirzepatide Tirzepatide fasting insulin change](https://healthrx.com/how-zepbound-affects/fasting-insulin)

![zepbound plateau strategy: woman checking her watch on a morning park walk](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/titration-zepbound/plateau-strategy.webp)

When progress stalls on a higher dose, steady daily habits and a conversation with a clinician are the next steps to weigh. Full zepbound efficacy plateau guide and sources at [healthrx.com/titration-zepbound](https://healthrx.com/titration-zepbound).

> Compounded drugs are not FDA-approved or reviewed by FDA for safety, effectiveness, or quality before marketing.
